Bavarian Nordic data shows booster shot protects against Omicron

A phase II study has demonstrated that the biotech firm’s Covid-19 vaccine candidate still provides a high level of protection against Omicron, although antibody levels were lower compared to all previously reported variants.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotech firm Bavarian Nordic has demonstrated in a phase II trial that vaccine candidate ABNCoV2 provides protection against the currently dominant Covid-19 variant, Omicron, the company announced in a Thursday press release.

According to the firm, the vaccine showed ”a significant boost to the neutralizing antibodies against the Omicron variant” in the majority of study participants, though the reported antibody levels were lower compared to all previously reported variants of SARS-CoV-2.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs